Unjha Formulations Limited (531762) Fair Value & Analysis
Healthcare · IN · Market cap ₹33.6M
Fair value as of: Jul 4, 2026
From 23 valuation models · updated today
Share price −4.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹17.55 – ₹28.85 · fair‑value band ₹25.95 – ₹43.25 · the ₹18.55 price screens below the ₹34.60 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Unjha Formulations Limited (531762) currently trades at ₹18.55, while our model-based Fair Value estimate is ₹34.60 — implying the stock looks roughly 86.5% undervalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Unjha Formulations Limited generated revenue of ₹93.4M at a net margin of 1.7%. Revenue declined 25.1% year over year. It earns a return on equity of 7.3%. The stock trades on a trailing P/E of 21.0. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Unjha Formulations Limited manufactures and sells ayurvedic products in India. The company offers sat-isabgol and isabgo husk formulation in elaichi flavor under the Anchor name; and isabgol powder in orange flavor under the Fibron and Fibron SF names, as well as natural fiber drink products. It also exports its products. The company was incorporated in 1994 and is based in Sidhpur, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Unjha Formulations Limited reported revenue of ₹156M in FY2026 versus ₹142M in FY2022, a compound +2.4%/yr. Reported net income was ₹7.0M in FY2026, compounding +29.3%/yr from FY2022.
Is 531762 fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Major stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Syncom Formulations (India) Limited 524470 | ₹14.23 | ₹10.20 | -28% |
| Makers Laboratories Limited 506919 | ₹151.45 | ₹105.20 | -31% |
| Syschem (India) Limited 531173 | ₹40.64 | ₹6.95 | -83% |
| Colinz Laboratories Limited 531210 | ₹77.55 | ₹14.60 | -81% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| UnitedHealth Group UNH | 7,169 MXN | 5,226 MXN | -27% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Unjha Formulations Limited (531762) undervalued?
What is the fair value of 531762?
What is the quality score of 531762?
What is the revenue of Unjha Formulations Limited (531762)?
What is the net profit margin of 531762?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.